Sometimes getting there is the hardest part
Bridging the Valley of Death
In collaboration with pioneering researchers at the forefront of small molecule innovation, we are building a robust pipeline of technology and talent to reshape the Kentucky biotech ecosystem and advance the next generation of life-changing pharmaceuticals
BG- 101
Lipid delivered anti-fibrotic to improve remodeling following acute myocardial infarction (MI). In March of 2025, our collaborators were awarded the NHLBI Catalyze grant to examine dosage and timing spanning small and large animal models of MI.
BG- 102
Lipid delivered immunomodulator to treat Spinal Cord Injury. Through the targeted reduction of site specific inflammation, it reduces pain, accelerates recovery and improves mobility.
BG- 859
Novel G-protein selective ligand for pain management. This full agonist opioid shares the rapid onset of fentanyl but without the dose limiting respiratory depression or wooden chest syndrome while providing 4x the analgesic duration.
